Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, Axiogenesis Ink Marketing Deal for iPSC-based Assays

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has signed an agreement to market Axiogenesis' mouse-induced pluripotent stem cell-derived cardiomyocytes and smooth muscle cells for preclinical cardiotoxicity screening.

The Sigma Life Science business of Sigma-Aldrich will offer the products as ready-to-order cells, application-specific kits, and custom services. Financial and other terms of the agreement were not disclosed.

The deal announced today builds on an earlier agreement signed by Sigma-Aldrich granting it worldwide rights to Kyoto University's induced pluripotent stem cell patent portfolio.

"This partnership deepens Sigma Life Science's commitment to alleviate critical deficiencies in ADME/toxicology screening and preclinical development through application of iPS cell technology recently licensed from Kyoto University, CompoZr Zinc Finger Nucleases, and the SAGEspeed Custom Animal Model Development program," John Listello, market segment manager of stem cell research and regenerative medicine at Sigma Life Science, said in a statement.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.